Please login to the form below

PPRS

This page shows the latest PPRS news and features for those working in and with pharma, biotech and healthcare.

newly agreed 2019 Voluntary Scheme for Branded Medicines Pricing and Access (formerly known as the PPRS) and, of course, Brexit.

New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake

Decades old PPRS name to go. The UK government and the pharmaceutical industry organisation the ABPI have unveiled a new 5 year pricing deal, called the ‘Voluntary scheme for branded medicines ... The new agreement is set to come into force in January
MS and cholesterol drugs picked for new UK rapid uptake push

Two major concerns currently hovering over the sector are the ongoing renegotiation of the main pricing agreement the PPRS, as well, of course, as.
Bayer to challenge Avastin legal ruling

The row has erupted at a crucial juncture: The UK industry organisation the ABPI is in the midst of an all-important renegotiation of the PPRS pricing agreement, with the deadline
Health secretary’s ‘rip off’ remarks anger UK pharma

drugs as well as the current negotiations to replace the PPRS pricing agreement. ... with worries that the government may take similar approach in the PPRS negotiations.
ABPI hits out at ‘punitive’ UK medicines cost controls

Yesterday saw the government unveil its plans for an updated Statutory Scheme, a ‘back up’ plan for companies not in the main PPRS pricing system. ... Any souring in relations with the government on the statutory scheme would be bad news, as the two

More from news
Approximately 11 fully matching, plus 112 partially matching documents found.

The UK’s new medicines pricing deal – opportunities and risks for pharma

So what are the big differences between the 2014 PPRS and the 2019 VPAS? ... Value assessment and managing uncertainty. Value assessment was in the 2014 PPRS, and it remains in the 2019 VPAS.
The new UK government-pharma industry pricing agreement – welcome news, but there are lessons to be learnt

It has achieved a 2% annual growth rate in the 2019 PPRS: a rate better than in each and every year of the 2014 PPRS. ... And, to me, there are three. The first is that the government has threatened the industry during every recent PPRS negotiation with
The UK’s new five-year pricing agreement

The deal, which replaces the long-standing PPRS agreement, includes a cap of 2% growth on the total medicines bill for each year of the agreement, with any NHS spending over
Comment: the new UK pricing deal – welcome news, but lessons to be learned

They have achieved a 2% annual growth rate in the 2019 PPRS: a rate better than in each and every year of the 2014 PPRS. ... And to me, there are three. The first is that the Government has threatened the industry during every recent PPRS negotiation
Brexit: can pharma 'take back control' of the narrative?

It sets a very concerning tone for the PPRS negotiations and underestimates the positive impact of R&D investment.

More from intelligence
Approximately 2 fully matching, plus 19 partially matching documents found.

EFPIA's Richard Torbett to move to the ABPI

with the Department of Health around the PPRS.”. ... At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.
ABPI names Amgen’s UK head as president

of Health to secure the 2014 PPRS.
ABPI appoints value and access manager

initiatives. “These include the implementation of the new PPRS scheme, working with NICE on value based assessment and helping our members with the changing NHS landscape whilst continuing to push for
Pfizer's Jonathan Emms to be ABPI president

The UK industry is in the midst of preparing for the introduction of the new version of the Pharmaceutical Pricing Regulatory Scheme ( PPRS) in January, final details of which were published ... Emms' appointment comes after he and his company expressed

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Let's be ambitious for patients and life sciences investment in Global Britain

Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals.
Hanover Communications

Since this Pharmaceutical Industry Competitiveness Task Force report in 2005, there have been at least five UK life science strategies plus three PPRS or VPAS deals.
Unique forum will unite NHS and industry to drive innovation

will be a panellist on a session about‘Negotiating the PPRS – Assessing what comes next’. . ... An overview of the agenda . Candid and open discussion about access and pricing as the deadline for completing PPRS negotiations

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Add my company

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...
When Will We Be Back To Normal?: The definitive question of 2021, whether you’re a homeschooling parent, a homebound professional, a wanderer with nowhere to go… or all three at once....
How to tell your healthcare story.: Healthcare research is not a simple story and the people in charge of those moments need to be careful about the story that they tell....